SAB Biotherapeutics (SABS) Total Current Liabilities (2020 - 2026)

SAB Biotherapeutics' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $9.9 million for Q1 2026.

• Quarterly Total Current Liabilities rose 2.06% year-over-year to $9.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.9 million (up 2.06% YoY) and the FY2025 annual result came in at $10.7 million, up 33.86% from the prior year.
• Total Current Liabilities was $9.9 million for Q1 2026 at SAB Biotherapeutics, down from $10.7 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $19.3 million in Q1 2022 and bottomed at $7.6 million in Q2 2024.
• A 5-year average of $11.6 million and a median of $10.7 million in 2025 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 23988.3% — and 2023, when it slumped 46.14%.
• SAB Biotherapeutics' Total Current Liabilities stood at $15.0 million in 2022, then dropped by 27.88% to $10.8 million in 2023, then retreated by 26.21% to $8.0 million in 2024, then surged by 33.86% to $10.7 million in 2025, then declined by 7.76% to $9.9 million in 2026.
• Business Quant data shows SABS's Total Current Liabilities at $9.9 million in Q1 2026, $10.7 million in Q4 2025, and $10.8 million in Q3 2025.